44th week of 2014 patent applcation highlights part 44 |
Patent application number | Title | Published |
20140322122 | POROUS NANOSTRUCTURED POLYIMIDE NETWORKS AND METHODS OF MANUFACTURE - Porous three-dimensional networks of polyimide and porous three-dimensional networks of carbon and methods of their manufacture are described. For example, polyimide aerogels are prepared by mixing a dianhydride and a diisocyanate in a solvent comprising a pyrrolidone and acetonitrile at room temperature to form a sol-gel material and supercritically drying the sol-gel material to form the polyimide aerogel. Porous three-dimensional polyimide networks, such as polyimide aerogels, may also exhibit a fibrous morphology. Having a porous three-dimensional polyimide network undergo an additional step of pyrolysis may result in the three dimensional network being converted to a purely carbon skeleton, yielding a porous three-dimensional carbon network. The carbon network, having been derived from a fibrous polyimide network, may also exhibit a fibrous morphology. | 2014-10-30 |
20140322123 | METAL ORGANIC FRAMEWORK COMPOUNDS - The invention provides novel Zr MOFs, in particular compounds having a surface area of at least 1020 m | 2014-10-30 |
20140322124 | METHOD OF PROCESSING DISCHARGE GAS DISCHARGED FROM PRODUCTION PROCESS OF GALLIUM NITRIDE COMPOUND SEMICONDUCTOR - The present invention provides a method of processing discharge gas containing ammonia, hydrogen, nitrogen, and an organic metal compound discharged from the production process of a gallium nitride compound semiconductor. The discharge gas is brought into contact with a cleaning agent prepared by impregnating an alkali metal compound with a metal oxide to remove the organic metal compound from the discharge gas. The discharge gas from which an organic metal compound is removed is brought into contact with an ammonia decomposition catalyst on heating to decompose the ammonia into nitrogen and hydrogen. The discharge gas in which ammonia is decomposed is brought into contact with palladium alloy membrane on heating to recover hydrogen that has penetrated through the palladium alloy membrane. After an organic metal compound is removed to liquefy the ammonia contained in the discharge gas as described above, a pressurization process and a cooling process is conducted by a heat pump to pressurize and cool the discharge gas from which an organic metal compound is removed to liquefy the ammonia contained in the discharge gas and separate the liquefied ammonia from hydrogen and nitrogen so as to recover the liquefied ammonia. The recovered hydrogen and ammonia are supplied to and reused in the production process of a gallium nitride compound semiconductor. | 2014-10-30 |
20140322125 | RECOVERY OF SULFUR TRIOXIDE HEAT OF ABSORPTION - A contact process for manufacture of sulfuric acid is disclosed in which the vapor phase heat of formation of sulfuric acid in the sulfur trioxide conversion gas and the heat of absorption of SO | 2014-10-30 |
20140322126 | ZEOLITE, MANUFACTURING METHOD OF THE SAME, AND CATALYTIC CRACKING BATALYST OF PARAFFIN - Provided is a beta-type zeolite which has a high catalytic activity and is not easily deactivated. | 2014-10-30 |
20140322127 | METAL DOPED ZEOLITE AND PROCESS FOR ITS PREPARATION - A metal-doped or metal-exchanged zeolite is disclosed, wherein the doping metal is present in the zeolite in the form of individual atoms i.e. as monomeric and/or dimeric species. Further, a process for the preparation of such a metal-doped or metal-exchanged zeolite is disclosed. The metal-doped zeolites are useful, in particular, as catalysts for the reduction of nitrogen oxides. | 2014-10-30 |
20140322128 | Materials and Methods Useful to Induce Cell Death via Methuosis - The present invention provides materials and methods to induce cell death by methuosis, a non-apoptotic cell death mechanism. Small molecules herein are useful for treating cell proliferation disorders or anomalies, particularly, but not exclusively, cancer. Methods related to the research and pharmaceutical use of the small molecules are also provided herein. | 2014-10-30 |
20140322129 | ANTI-B7-H4 ANTIBODIES AND IMMUNOCONJUGATES - The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same. | 2014-10-30 |
20140322130 | SPECIFIC BINDING PROTEINS AND USES THEREOF - The present invention relates to specific binding members, particularly antibodies and fragments thereof, which bind to EGFR on tumor cells that overexpress EGFR, and on tumor cells that express the truncated version of the EGFR receptor, de2-7 EGF. In particular, the epitope recognized by the specific binding members, particularly antibodies and fragments thereof, is enhanced or evident upon aberrant post-translational modification. These specific binding members are useful in the diagnosis and treatment of cancer. The binding members of the present invention may also be used in therapy in combination with chemotherapeutics or anti-cancer agents and/or with other antibodies or fragments thereof. | 2014-10-30 |
20140322131 | Methods and Agents for the Diagnosis and Treatment of Hepatocellular Carcinoma - The present invention relates to methods of diagnosing and methods of treating hepatocellular carcinoma in a subject. The invention also relates to antagonists of PLVAP proteins, such as antibodies that specifically bind PLVAP proteins, as well as compositions and kits comprising antagonists of PLVAP proteins. The invention further relates to humanized antibodies that specifically bind PLVAP protein. | 2014-10-30 |
20140322132 | FRAGMENTS OF P97 AND USES THEREOF - Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (BBB) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the BBB. | 2014-10-30 |
20140322133 | TSPO-TARGETING COMPOUNDS AND USES THEREOF - Translocator protein (TSPO) targeting compounds are described. Methods of making the compounds, and uses of the compounds for imaging are also described. | 2014-10-30 |
20140322134 | Treatment and Imaging Methods Using Antibodies to Aminophospholipids - Disclosed are the surprising discoveries that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are stable and specific markers accessible on the luminal surface of tumor blood vessels, and that the administration of an anti-aminophospholipid antibody alone is sufficient to induce thrombosis, tumor necrosis and tumor regression in vivo. This invention therefore provides anti-aminophospholipid antibody-based methods and compositions for use in the specific destruction of tumor blood vessels and in the treatment of solid tumors. Although various antibody conjugates and combinations are thus provided, the use of naked, or unconjugated, anti-phosphatidylserine antibodies is a particularly important aspect of the invention, due to simplicity and effectiveness of the approach. | 2014-10-30 |
20140322135 | CELL THERAPY FOR MYELODYSPLASTIC SYNDROMES - The invention provides methods for treating myelodysplastic syndrome (MDS). The invention is generally directed to reducing certain overt symptoms and disease-causing biological events in MDS by administering certain cells to a subject having MDS. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to affect these events. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired potency for affecting these events. | 2014-10-30 |
20140322136 | METHODS FOR TREATING OBESITY - The present invention provides methods to reduce or inhibit weight gain by administering inhibitors of the SirT1 protein to a subject. Methods to identify such inhibitors are also disclosed. | 2014-10-30 |
20140322137 | Detection Of Targeted Biological Substances Using Magnetic Relaxation Of Individual Nanoparticles - The present invention can provide a method of determining the presence, location, quantity, or a combination thereof, of a biological substance, comprising: (a) exposing a sample to a plurality of targeted nanoparticles, where each targeted nanoparticle comprises a paramagnetic nanoparticle conjugated with one or more targeting agents that preferentially bind with the biological substance, under conditions that facilitate binding of the targeting agent to at least one of the one or more biological substances; (b) subjecting the sample to a magnetic field of sufficient strength to induce magnetization of the nanoparticles; (c) measuring a magnetic field of the sample after decreasing the magnetic field applied in step b below a threshold; (d) determining the presence, location, quantity, or a combination thereof, of the one or more biologic substances from the magnetic field measured in step (c). | 2014-10-30 |
20140322138 | METHOD OF RELIABLE PARTICLE SIZE CONTROL FOR PREPARING AQUEOUS SUSPENSION OF PRECIOUS METAL NANOPARTICLES AND THE PRECIOUS METAL NANOPARTICLE SUSPENSION PREPARED BY THE METHOD THEREOF - Disclosed is a method for making a colloidal suspension of precious metal nanoparticles. The method comprises providing a target material comprising a precious metal in a liquid dispersion medium in an ablation container. The dispersion medium has an electrical conductivity within a predetermined conductivity range. Laser pulses are used to generate the nanoparticles from the target in the container. While generating the nanoparticles the electrical conductivity of the dispersion medium is monitored and maintained within the predetermined range and thereby the generated nanoparticles are produced within a predetermined size range. The generated nanoparticles are used to form a colloidal suspension. | 2014-10-30 |
20140322139 | STABILIZATION OF X-RAY DIAGNOSTIC COMPOSITION - The invention relates to a composition comprising a non-ionic X-ray contrast agent in a pharmaceutically acceptable carrier, and particularly to a supersaturated X-ray composition comprising X-ray contrast agents with a high dissolution temperature in water. Particularly, the invention provides such composition which is stable, and wherein crystallisation during storage is avoided. In a preferred aspect the X-ray contrast agent is Ioforminol and the composition includes a nucleation- and growth inhibitor. The invention further relates to a process for the preparation of such stable diagnostic X-ray composition. | 2014-10-30 |
20140322140 | ORAL CARE COMPOSITIONS COMPRISING COLOR CHANGING FILMS - Described herein are powder coated films comprising a polymer matrix designed for use in a children's toothpaste, compositions comprising the films; and methods of making and using the same. | 2014-10-30 |
20140322141 | FILM CONTAINING COMPOSITIONS - Described herein are compositions comprising a film, wherein the film comprises a pigment, and is adapted to release the pigment at a specific point in time during use; and methods of making and using the same. | 2014-10-30 |
20140322142 | PARTICLE SIZE REDUCTION OF AN ANTIMUSCARINIC COMPOUND - A stable crystalline micronized particulate of a glycopyrronium salt may be prepared by suspending the drug in a water-immiscible anti-solvent in which the drug has little or no solubility and micronizing the suspension. The resulting drug particles are physically stable with regard to agglomeration and/or aggregation on storage. | 2014-10-30 |
20140322143 | WATER-ABSORBENT ADHESIVE COMPOSITIONS AND ASSOCIATED METHODS OF MANUFACTURE AND USE - An adhesive composition is provided that is water-insoluble yet water-absorbent, i.e., capable of absorbing up to 15 wt. % water or more. The composition in composed of a film-forming hydrophilic polymer with at least one linear segment having a plurality of recurring polar groups along the polymer backbone, a complementary multifunctional polymer with a plurality of recurring functional groups that noncovalently bind to the polar groups on the film-forming polymer, and plasticizer. A method for manufacturing the adhesive composition is provided as well. | 2014-10-30 |
20140322144 | ALKALINE COMPOSITIONS AND THEIR DENTAL AND MEDICAL USE - The present invention relates to antimicrobial alkaline compositions suitable for use in medical and dental treatment. The compositions comprise a polyalkylene glycol or C | 2014-10-30 |
20140322145 | ANTIMICROBIAL COMPOSITION - The present invention relates to an antimicrobial composition and a method for disinfection involving the antimicrobial composition. It particularly relates to an antimicrobial composition for personal cleaning, oral care or hard surface cleaning applications. It was found that compositions comprising thymol, selected antimicrobial alcohols and a carrier provide synergistic antimicrobial action. In a preferred aspect the composition also comprises 1 to 80%-wt of one or more surfactants. | 2014-10-30 |
20140322146 | METHODS OF PREPARING NON-ALCOHOL BIOACTIVE ESSENTIAL OIL MOUTH RINSES - The invention relates generally to liquids such as mouth rinses for the prevention and elimination of bad breath as well as for the reduction of oral microorganisms responsible for the development of dental plaque and tooth decay. In particular, the present invention relates to a method of preparing non-alcohol or reduced alcohol mouth rinses effective at preventing the above-mentioned problems. | 2014-10-30 |
20140322147 | ANTIMICROBIAL COMPOSITION - Disclosed herein are antimicrobial compositions and methods of producing an antimicrobial effect in which a citrus extract such as Biosecur® is used in combination with benzyl alcohol and one or more additional agent selected from the group consisting of lauroyl arginate/glyceryl laurate and essential oils or constituents thereof such as galangal oil, thyme oil, thymol, cinnamon leaf oil, cinnamon bark oil, lemongrass oil, orange oil, pine oil, cedarwood oil, curry leaf oil, and rosemary oil. These compositions may be used as natural preservatives for personal care products, foods, beverages, and as topical or surface disinfectants. | 2014-10-30 |
20140322148 | Oil Compositions and Methods for Increasing Hair Growth and/or Preventing Hair Loss - Described herein are topical oil-based formulations that find use in the treatment of alopecia, i.e., hair loss, and in the promotion of hair growth. | 2014-10-30 |
20140322149 | COMPOUND USEFUL FOR TREATING CELLULITE - The use of propionyl L-carnitine for treating disturbances of the skin such as cellulite is described. | 2014-10-30 |
20140322150 | PREVENTING OR AMELIORATING AGENT FOR PIGMENTATION - An object is to provide an external preparation for skin preferably usable to prevent or ameliorate pigmentation. The object is achieved by providing a preventing or ameliorating agent for pigmentation, consisting of a compound represented by the following general formula (1), an isomer thereof, and/or a pharmacologically acceptable salt thereof, and an external preparation for skin containing the same as a component: | 2014-10-30 |
20140322151 | Use Of Isosorbide Caprylates/Caprates In Deodorants And Antiperspirants - Disclosed is the use of compositions containing one or more isosorbide capryiates/caprates in antiperspirants and deodorants for improving the action thereof in reducing body odor. The improvement of the action of the antiperspirants and deodorants relates especially to the intensity of reducing body odor and/or to the duration of reducing body odor. | 2014-10-30 |
20140322152 | WATER IN OIL EMULSIONS WITH HIGH WATER CONTENT - The present invention generally relates to a water-in-oil emulsion comprising at least one oil-soluble polar modified polymer and at least one polylysine, wherein the emulsion has a high water content. | 2014-10-30 |
20140322153 | Lubricating Skin Engaging Member - A skin engaging member for use on a hair removal device, said skin engaging member comprising: a carrier having a skin contacting surface, said skin contacting surface forming at least one orifice; and a lubricating material releasably engaged with said carrier, said at least one orifice exposing at least a portion of said lubricating material; wherein the lubricating material comprises a copolymer of polyethylene oxide and polypropylene oxide. | 2014-10-30 |
20140322154 | Method for Lengthening Keratin Fibers - There is a method for lengthening keratin fibers. The method has the steps of a) applying to the keratin fibers a composition having a solvent and one or more polymers soluble or solubilizable in the solvent b) allowing the solvent to evaporate. The composition is applied in an amount sufficient to lengthen the keratin fibers. There are also other methods for lengthening keratin fibers. There is also a mascara composition. | 2014-10-30 |
20140322155 | GEL CARRIER FOR RELEASING ACTIVE INGREDIENTS - A gel carrier for releasing active ingredients is formed from a co-polymer blend and an active ingredient blend. The co-polymer blend and active ingredient blend are combined and allowed to cool to a desired temperature. When the gel carrier floats in, is immersed, or is exposed to water-based materials, active ingredients are leached out of the gel carrier. | 2014-10-30 |
20140322156 | PROCESS FOR REDUCING MALODOURS - The use of 2-amino-1,3-propanediol and/or substituted 2-amino-1,3-propanediol for degradation of malodours caused by the presence of acids, thiols, sulphides, amines, aromatics, alcohols and/or heteroaromatics is described. By addition of 2-amino-1,3-propanediol and/or substituted 2-amino-1,3-propanediol to the ambient air or, for example, incorporated into washing compositions, it is possible to reduce corresponding malodours. | 2014-10-30 |
20140322157 | Bi-Functional Co-Polymer Use for Ophthalmic and Other Topical and Local Applications - The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided. | 2014-10-30 |
20140322158 | METHODS OF TREATING A SUBJECT AFFLICTED WITH AN AUTOIMMUNE DISEASE USING PREDICTIVE BIOMARKERS OF CLINICAL RESPONSE TO GLATIRAMER ACETATE THERAPY IN MULTIPLE SCLEROSIS - A method for treating a subject afflicted with an autoimmune disease with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of administering a therapeutic amount of the pharmaceutical composition to the subject, determining whether the subject is a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder by measuring the value of a biomarker selected from the group consisting of IL-10 concentration, IL-17 concentration, IL-18 concentration, TNF-α concentration, BDNF concentration, caspase-1 concentration, IL-10/IL-18 ratio and IL-10/IL-17 ratio in the blood of the subject, and comparing the measured value to a reference value for the biomarker to identify the subject as a glatiramer acetate responder or a glatiramer acetate hypo-/non-responder, and continuing the administration if the subject is identified as a glatiramer acetate responder, or modifying treatment of the subject if the subject is identified as a glatiramer acetate hypo-/non-responder. | 2014-10-30 |
20140322159 | ODORS FOR PSYLLID TRAPPING, REPELLING AND CONTROL - The disclosure provides methods and compositions for modifying psyllid behavior. In addition, the disclosure provides methods and volatile odorants useful for repelling or attracting psyllids. | 2014-10-30 |
20140322160 | METHOD AND COMPOSITION FOR ALTERING A B CELL MEDIATED PATHOLOGY - The present invention provides compositions for altering a B cell mediated pathology in a patient. The compositions may comprise at least one and/or two chimeric proteins. Each chimeric protein comprises at least a portion of either the VH or VL region of an immunoglobulin module from particular B cells from a patient having a B cell mediated pathology, and an immunoglobulin constant region. The genes encoding VH and/or VL regions and the genes encoding immunoglobulin constant regions are isolated and inserted in an expression vector. The chimeric proteins may be produced by introducing the expression vectors into insect cell lines. Proteins may be further purified and conjugated to a compound such as a immunogenic carrier. | 2014-10-30 |
20140322161 | ANTI-IL-6 VACCINE COMPOSITION - The present invention relates to a pharmaceutical composition comprising, by way of active ingredient, at least one polypeptide comprising, or constituted by a sequence constituted by at least 8 contiguous amino acids and from at the most 30 contiguous amino acids chosen from within the interleukin-6 sequence and from at the most 30 contiguous amino acids chosen from within the complete IL-6 sequence. | 2014-10-30 |
20140322162 | Use of Ferritin to Treat Iron Disorders - Methods and compositions for treating an iron disorder in a patient are presented, including methods for orally administering a recombinant yeast that produces H-ferritin-iron complex or the H-ferritin-iron complex extracted from the yeast. Data indicate that administration of the recombinant yeast more effectively increases hemoglobin, hematocrit and transferrin saturation than an iron-equivalent amount of FeSO | 2014-10-30 |
20140322163 | NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE - Monoclonal neutralizing antibodies that specifically bind to HIV-1 gp120 and antigen binding fragments of these antibodies are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. Methods for detecting HIV using these antibodies are disclosed. In addition, the use of these antibodies, antigen binding fragment, nucleic acids and vectors to prevent and/or treat an HIV infection is disclosed. | 2014-10-30 |
20140322164 | METHOD OF ASSESSING RISK OF PML - The invention relates to methods of assessing a patient's risk of developing Progressive multifocal leukoencephalopathy (PML). | 2014-10-30 |
20140322165 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE - The present invention provides, among other things, compounds represented by the general Formula I: | 2014-10-30 |
20140322166 | GENE EXPRESSION SIGNATURES FOR DETECTION OF UNDERLYING PHILADELPHIA CHROMOSOME-LIKE (PH-LIKE) EVENTS AND THERAPEUTIC TARGETING IN LEUKEMIA - The invention provides arrays, systems, devices, methods, computer-readable media and kits that enable expression-based classification of B-precursor acute lymphoblastic leukemia (ALL) as being either responsive or non-responsive to tyrosine kinase inhibitor mono or co-therapy. | 2014-10-30 |
20140322167 | PROCESS FOR BIOLOGICALLY COMBATING PSEUDOMONAS - The invention relates to a method for controlling the proliferation of | 2014-10-30 |
20140322168 | PAENIBACILLUS ALVEI STRAIN TS-15 AND ITS USE IN CONTROLLING PATHOGENIC ORGANISMS ON CROPS - The present invention provides a newly isolated bacterial strain of | 2014-10-30 |
20140322169 | Recombinant Virus Products and Methods for Inhibition of Expression of DUX4 - The present invention relates to RNA interference-based methods for inhibiting the expression of the DUX4 gene, a double homeobox gene on human chromosome 4q35. Recombinant adeno-associated viruses of the invention deliver DNAs encoding microRNAs that knock down the expression of DUX4. The methods have application in the treatment of muscular dystrophies such as facioscapulohumeral muscular dystrophy. | 2014-10-30 |
20140322170 | Fermented Flavoring System Derived from Greek Yogurt Processing - Disclosed are methods for producing flavoring ingredients, ready-to-drink formulations, protein powder mixes and pre-mixes, yogurt-flavored cereal binders for use in cereal clusters and bars, etc., from Greek yogurt whey (i.e., Greek acid whey). | 2014-10-30 |
20140322171 | USE OF CHROMOBACTERIUM SUBSTUGAGE FORMULATIONS, COMPOSITIONS AND COMPOUNDS TO MODULATE CORNWORM ROOTWORM LARVAE INFESTATION - Provided is the use of or compositions or formulations comprising | 2014-10-30 |
20140322172 | LIPID METABOLISM AND/OR SUGAR METABOLISM IMPROVER CONTAINING LACTIC ACID BACTERIUM OR TREATMENT PRODUCT THEREOF - This invention provides the use of a microorganism capable of improving both lipid metabolism and sugar metabolism. Specifically, the invention relates to: a lipid metabolism and/or sugar metabolism improver comprising, as an active ingredient, a bacterial cell selected from bacteria belonging to the genus | 2014-10-30 |
20140322173 | Oncolytic Vaccinia Virus Combination Cancer Therapy - Embodiments of the invention are directed methods that include a thymidine kinase deficient vaccinia virus. The methods include evaluating a tumor for reperfusion after treatment with vaccinia virus and administering an anti-angiogenic agent if reperfusion is detected. | 2014-10-30 |
20140322174 | NOVEL BACTERIOPHAGES - The present invention provides a bacteriophage with effective antibacterial activity against | 2014-10-30 |
20140322175 | Use Of Umbilical Cord Blood To Treat Individuals Having A Disease, Disorder Or Condition - The present invention provides methods of using cord blood and cord blood-derived stem cells in high doses to treat various conditions, diseases and disorders. The high-dose cord blood and cord blood-derived stem cells have a multitude of uses and applications, including but not limited to, therapeutic uses for transplantation and treatment and prevention of disease, and diagnostic and research uses. In particular, the cord blood or cord blood-derived stem cells are delivered in high doses, e.g., at least 3 billion nucleated cells per treatment, where treatment may comprise a single or multiple infusions. The invention also provides for the use of cord blood or cord blood-derived stem cells from multiple donors without the need for HLA typing. | 2014-10-30 |
20140322176 | METHODS OF USING ZSCAN4 FOR REJUVENATING HUMAN CELLS - The present disclosure relates to methods for increasing telomere length in one or more human adult cells and/or increasing genome stability of one or more human adult cells, for example by contacting one or more human adult cells with an agent that increases expression of Zscan4 in the one or more human adult cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a telomere abnormality, of rejuvenating one or more human adult cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human adult cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 is also provided. | 2014-10-30 |
20140322177 | METHODS AND COMPOSITONS FOR TREATMENT OF BONE DEFECTS WITH PLACENTAL CELL POPULATIONS - Provided herein are osteogenic placental adherent cells (OPACs), methods of using OPACs and OPAC populations, and methods of culturing, proliferating, expanding, or differentiating the OPACs. Further provided herein are methods of using the OPACs to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with OPACs and compositions comprising OPACs. Also provided herein are methods of using OPACs in the treatment and management of multiple myeloma, e.g., reducing the progression of, halting the progression of, or improving, one or more symptoms of multiple myeloma in an individual having multiple myeloma, comprising administering a plurality of OPACs to the individual. | 2014-10-30 |
20140322178 | EXPANDING HEMATOPOIETIC STEM CELLS - A method of expanding hematopoietic stem cells. Also disclosed is a method of diagnosing primary or secondary bone marrow failure syndrome. The invention further includes a method of treating primary or secondary bone marrow failure syndrome. | 2014-10-30 |
20140322179 | METHODS OF GENERATING GLIAL AND NEURONAL CELLS AND USE OF SAME FOR THE TREATMENT OF MEDICAL CONDITIONS OF THE CNS - A method of generating neural and glial cells is provided. The method comprising growing human stem cells under conditions which induce differentiation of said human stem cells into the neural and glial cells, said conditions comprising the presence of retinoic acid and an agent capable of down-regulating Bone Morphogenic Protein activity. | 2014-10-30 |
20140322180 | USE OF MESENCHYMAL STEM CELLS FOR COMPLETELY REPOPULATING HOST TISSUE - A method of treating a genetic disease or disorder such as, for example, cystic fibrosis, Wilson's disease, amyotrophic lateral sclerosis, or polycystic kidney disease, in an animal comprising administering to said animal mesenchymal stem cells in an amount effective to treat the genetic disease or disorder in the animal. | 2014-10-30 |
20140322181 | USE OF HUMAN CORD BLOOD-DERIVED PLURIPOTENT CELLS FOR THE TREATMENT OF DISEASE - The present invention features methods of organ tissue regeneration using pluripotent cells derived from umbilical cord blood, compositions of these pluripotent cells, methods for further transforming these cells, and uses for these transformed cells. | 2014-10-30 |
20140322182 | Canine Amniotic Membrane-Derived Multipotent Stem Cells - The present invention relates to canine amniotic membrane-derived multipotent stem cells (cAM-MSCs) and preparation method thereof. More particularly, the present invention relates to canine amniotic membrane-derived multipotent stem cells, which show negative immunological properties on human markers CD3, CD11c, CD28, CD34, CD38, CD41a, CD45, and CD62L and positive immunological properties on human markers CD90 and CD105, and have the ability to be maintained in an undifferentiated state for 20 passages or more and the ability to be differentiated into fat, bones, nerves, cartilage, etc. | 2014-10-30 |
20140322183 | TARGETING CYTOTOXIC CELLS WITH CHIMERIC RECEPTORS FOR ADOPTIVE IMMUNOTHERAPY - The present invention provides compositions and methods for regulating the specificity and activity of T cells. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “KIR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR). | 2014-10-30 |
20140322184 | INDUCIBLE EXPRESSION CASSETTE, AND USES THEREOF - The invention relates to an expression cassette including a gene of interest under the control of an inducible promoter, characterized in that said inducible promoter includes at least one CARE regulatory sequence (C/EBP-ATF responsive element) and a minimal promoter. The invention also relates to a vector and a host cell, as well as to a pharmaceutical composition including such a cassette, and to the use thereof for treating diseases by gene therapy. | 2014-10-30 |
20140322185 | SIALIC ACID PRODUCING BACTERIA - The present invention generally relates to the field of sialic acids, in particular to the field of sialic acid enriched food products and their uses. One embodiment of the present invention relates to a food product enriched with food-grade sialic acid producing bacteria and/or a fraction thereof containing sialic acid. | 2014-10-30 |
20140322186 | AGENT FOR PREVENTION OR AMELIORATION OF OBESITY - To provide a pharmaceutical product or food which has an excellent fat-accumulation-inhibiting activity and/or fat-metabolism-improving activity and which is effective for inhibition or improvement of obesity, fatty liver, etc. | 2014-10-30 |
20140322187 | MONOUNSATURATED FATTY ACID FOR NAILCARE - The invention relates to the cosmetic use of an effective amount of at least one monounsaturated fatty acid, of a salt thereof and/or of an ester thereof, as a nailcare active agent. | 2014-10-30 |
20140322188 | TOLERIZING TREATMENTS FOR AUTOIMMUNE DISEASE - The disclosure relates to methods of identifying a compound that comprises an epitope that induces immune tolerance in a patient suffering from an autoimmune disease. The disclosure further relates to methods of treating an autoimmune disease by administering (i) a compound identified by the methods described herein, (ii) regulatory T-cells from the patient or a compatible donor, or (iii) a combination of regulatory T-cells and a compound identified by the methods described herein. The disclosure further relates to methods of treating age-related macular degeneration and uveitis. | 2014-10-30 |
20140322189 | COMPOSITION BASED ON UBIDECARENONE - A composition based on ubidecarenone, or coenzyme Q10 or CoQ10, comprises CoQ10, one or more specific hydrophylic carriers selected from the maltodextrins class and one or more adjuvant agents selected from the sucrose-esters class. | 2014-10-30 |
20140322190 | Pharmaceutical Compositions and Methods for Digesting Atherosclerotic Plaques - Disclosed are pharmaceutical compositions and methods for digesting atherosclerotic plaques in a patient in need thereof. The compositions include and the methods utilize a mixture of collagenases for digesting plaques and optionally may include or utilize additional agents such as cyclodextrins, chelating agents, and tissue plasminogen activator. | 2014-10-30 |
20140322191 | MODIFIED FACTOR IX POLYPEPTIDES AND USES THEREOF - Modified Factor IX (FIX) polypeptides and uses thereof are provided. Such modified FIX polypeptides include FIXa and other forms of FIX. Among the modified FIX polypeptides provided are those that have altered activities, typically altered procoagulant activity, including increased procoagulant activities. Hence, such modified polypeptides are therapeutics. | 2014-10-30 |
20140322192 | PROTEOGLYCAN DEGRADING MUTANTS FOR TREATMENT OF CNS - The present disclosure relates to the preparation and deletion mutants of chondroitinase proteins and their use in methods for promoting the diffusion of therapeutic composition into tissues and their use for neurological functional recovery after central nervous system (“CNS”) injury or disease. | 2014-10-30 |
20140322193 | Therapies for Disorders of the Cornea and Conjunctiva - Unexpectedly, disorders of the cornea and conjunctiva are found to be caused or to be exacerbated, at least in part, by extracellular ATP and P2X7 receptor activation. Therapeutic compositions for topical administration to the eye for the treatment of disorders of the cornea and conjunctiva include an entity that inhibits P2X7 receptor function, reduces the effective concentration of extracellular ATP, or both. | 2014-10-30 |
20140322194 | Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, and pharmaceutical compositions comprising same - Methods for preparing Factor X, activated Factor X, inactivated factor X and inactivated factor Xa, compositions comprising Factor X and Factor Xa, inactivated Factor X and inactivated Factor Xa and methods of medical treatment using Factor X, Factor Xa, activated Factor X and inactivated Factor Xa are disclosed. The preparation methods comprise a chromatography step using an immobilised metal ion affinity chromatography substrate. | 2014-10-30 |
20140322195 | Factor IXA Inhibitors - The present invention provides a compound of Formula (I) | 2014-10-30 |
20140322196 | LACTOFERRIN DERIVED PEPTIDES FOR USE AS BROAD-SPECTRUM INHIBITORS OF INFLUENZA VIRUS INFECTION - The present disclosure describes lactoferrin C-lobe and peptides derived thereof used as broad spectrum inhibitors of Influenza virus group 1 and 2 hemagglutination and infection. | 2014-10-30 |
20140322197 | METHODS FOR TREATMENT OF HIP AND GROIN PAIN ASSOCIATED WITH FEMOROACETABULAR IMPINGEMENT (FAI) - Methods for treating or alleviating symptoms associated with femoroacetabular impingement (FAI) by local administration of a clostridial derivative, such as a botulinum toxin, to the hip capsule and surrounding muscle. | 2014-10-30 |
20140322198 | COMPOSITION COMPRISING VICENIN-2 HAVING A BENEFICIAL EFFECT ON NEUROLOGICAL AND/OR COGNITIVE FUNCTION - The invention relates to an active ingredient and/or to a composition having beneficial effect on neurological and cognitive functions. | 2014-10-30 |
20140322199 | METHODS OF TREATING CARDIOVASCULAR AND METABOLIC DISEASES - The technology described herein is directed to methods of treating cardiovascular and metabolic disorders. | 2014-10-30 |
20140322200 | COMBINATION THERAPY OF AN AFUCOSYLATED CD20 ANTIBODY WITH AN ANTI-VEGF ANTIBODY - The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with an anti-VEGF antibody for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and an anti-VEGF antibody. | 2014-10-30 |
20140322201 | METHODS OF TREATING MULTIPLE MYELOMA USING COMBINATION THERAPIES BASED ON ANTI-CS1 ANTIBODIES - Compositions and methods for treating MM are provided herein. | 2014-10-30 |
20140322202 | TREATMENT WITH ANTI ErbB2 ANTIBODIES - The present invention concerns the treatment of cancer with anti-ErbB2 antibodies. | 2014-10-30 |
20140322203 | FORMULATIONS WITH REDUCED OXIDATION - The invention provides formulations comprising a protein in combination with a compound that prevents oxidation of the protein. The invention also provides methods for making such formulations and methods of using such formulations. The invention further provides methods of screening for compounds that prevent oxidation of a protein in a protein composition and methods of preventing oxidation of a protein in a formulation. | 2014-10-30 |
20140322204 | TREATMENT AND PREVENTION OF VIRAL INFECTIONS - Disclosed is polynucleotide encoding a polypeptide comprising an antibody binding site, the polypeptide being able to bind to HCV E2 samples representative of each of HCV genotypes 1-6, as well as polypeptides having such properties and uses of such polypeptides in detecting and treating HCV infection. | 2014-10-30 |
20140322205 | RTEF-1 VARIANTS AND THE USE THEREOF FOR INHIBITION OF ANGIOGENESIS - Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD). | 2014-10-30 |
20140322206 | METHOD FOR TREATING ATROPHIC AGE RELATED MACULAR DEGENERATION - Compositions and methods for treating dry age related macular degeneration (dry AMO) by administration to an intraocular location of an anti-neovascular agent (such as bevacizumab) in either a liquid or solid polymeric vehicle (or both), such as a biodegradable hyaluronic acid or PLGA (or PLA). | 2014-10-30 |
20140322207 | METHODS OF IDENTIFYING CRITICALLY ILL PATIENTS AT INCREASED RISK OF DEVELOPMENT OF ORGAN FAILURE AND COMPOUNDS FOR THE TREATMENT HEREOF - The present invention relates to compounds for treatment that protects the endothelium, prevents pathologic thrombus formation in the microcirculation and preserves platelet number and function and thus may be related to minimizing or preventing development of organ failure, including multiple organ failure (MOF), and, hence, death in critically ill patients by administration of agent(s) limiting the platelets ability to aggregate and form clots and/or by agents modulating/preserving endothelial integrity and/or by agent(s) increasing the rate of thrombus lysis, and Another aspect of the invention related to by a cell-based whole blood viscoelastical haemostatic assay identifying critically ill patients at increased risk of development of organ failure, including multiple organ failure (MOF) and death. | 2014-10-30 |
20140322208 | TREATMENT OF HEMATOLOGIC MALIGNANCIES WITH AN ANTI-CXCR4 ANTIBODY - The present disclosure provides human monoclonal antibodies that bind specifically to CXCR4 with high affinity. This disclosure also provides a method for treating a subject afflicted with a CXCR4-expressing cancer, in particular a hematological malignancy such as multiple myeloma, acute myeloid leukemia, or non-Hodgkin's lymphoma, comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an anti-CXCR4 antibody of the disclosure. The disclosure further provides a kit for treating a cancer in a subject comprising a dose of an anti-CXCR4 antibody and instructions for using the anti-CXCR4 antibody in the therapeutic methods of the disclosure. | 2014-10-30 |
20140322209 | ADMINISTRATION OF ALPHA4BETA7 HETERO- DIMER-SPECIFIC ANTIBODY - There is provided a method of treating a subject afflicted with a condition that is associated with inappropriate trafficking of cells expressing alpha4beta7 to the gastrointestinal tract, comprising administering to the subject an alpha4beta7 heterodimer specific antibody in an amount and at an interval sufficient to ameliorate the condition. | 2014-10-30 |
20140322210 | ANTIBODIES USEFUL IN PASSIVE INFLUENZA IMMUNIZATION - Specific monoclonal antibodies and fragments including bispecific antibodies thereof that are crossreactive with multiple clades of influenza virus including both Group 1 and Group 2 representatives are disclosed. These antibodies are useful in controlling influenza epidemics and pandemics as well as in providing prophylactic or therapeutic protection against seasonal influenza. | 2014-10-30 |
20140322211 | TENASCIN-C AND USE THEREOF IN RHEUMATOID ARTHRITIS - The present invention provides a method of determining the rheumatoid arthritis status of a subject, or the progression of rheumatoid arthritis, or the appropriate treatment for a subject with rheumatoid arthritis, comprising the steps of (a) determining the level of tenascin-C in a sample from said subject; and (b) comparing the level of tenascin-C determined in step (a) with one or more reference values. Preferably the rheumatoid arthritis referred to is erosive rheumatoid arthritis. The be accompanied when published by FIG. | 2014-10-30 |
20140322212 | EFFECTIVE TARGETING OF PRIMARY HUMAN LEUKEMIA USING ANTI-CD123 CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS - The invention provides compositions and methods for treating leukemia, for example, acute myeloid leukemia (AML) and B-cell acute lymphoid leukemia (B-ALL). The invention also relates to at least one chimeric antigen receptor (CAR) specific to CD123, vectors comprising the same, and recombinant T cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD123 binding domain. The invention also includes methods of bone marrow ablation for use in treatments necessitating bone marrow reconditioning or transplant. | 2014-10-30 |
20140322213 | Pharmaceutical Composition for the Treatment of Type-1 Diabetes - A composition for the prevention or treatment of type I diabetes in a subject, said composition comprising a GABAergic and incretin exemplified by GABA and GLP-1/Ex4. These are optionally provided together in a single composition to promote beta-cell regeneration prevent beta-cell apoptosis and control autoimmunity for the prevention and treatment of T1D in mammals. | 2014-10-30 |
20140322214 | THERAPEUTIC APPLICATIONS OF ACTIVATION OF HUMAN ANTIGEN-PRESENTING CELLS THROUGH DECTIN-1 - The present invention includes compositions and methods for binding Dectin-1 on immune cells with anti-Dectin-1-specific antibodies or fragment thereof capable of activating the immune cells. | 2014-10-30 |
20140322215 | METHODS OF INHIBITING TUMOR GROWTH BY ANTAGONIZING IL-6 RECEPTOR - The present invention provides methods for inhibiting or attenuating tumor growth in a subject by administering an IL-6 antagonist to the subject. In certain embodiments, the methods of the invention are used to inhibit the growth of an anti-VEGF-resistant tumor in a subject. The IL-6 antagonist may be, e.g., an antibody that specifically binds IL-6R. The IL-6 antagonist may be administered in combination with a VEGF antagonist, and/or an EGFR antagonist. | 2014-10-30 |
20140322216 | GLYPICAN-3-SPECIFIC ANTIBODY AND USES THEREOF - The present invention relates to compositions and methods for diagnosing and treating diseases, disorders or conditions associated with dysregulated expression of GPC3. The invention provides novel antibodies that specifically bind to glypican-3 (GPC3). The invention also relates to a fully human chimeric antigen receptor (CAR) wherein the CAR is able to target GPC3. | 2014-10-30 |
20140322217 | NOVEL HETERODIMERIC PROTEINS - The invention provides heterodimeric antibodies comprising a first heavy chain comprising a first Fc domain and a single chain Fv region that binds a first antigen. The heterodimeric antibodies also comprise a second heavy chain comprising a second Fc domain, a first variable heavy chain and a first variable light chain, wherein the first and second Fc domains are different. | 2014-10-30 |
20140322218 | Antibody Constructs for CDH19 and CD3 - The present invention provides to a antibody construct comprising a first human binding domain capable of binding to human CDH19 on the surface of a target cell and a second domain capable of binding to human CD3 on the surface of a T cell. Moreover, the invention relates to a nucleic acid sequence encoding the antibody construct, a vector comprising said nucleic acid sequence and a host cell transformed or transfected with said vector. Furthermore, the invention relates a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct. | 2014-10-30 |
20140322219 | ANTI-FACTOR XI MONOCLONAL ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to compositions and methods for inhibiting thrombosis without compromising hemostasis. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-factor XI monoclonal antibodies of the invention, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier. Methods of the invention comprise administering the compositions described above to a subject in need thereof for the purpose of inhibiting thrombosis, reducing a required dose of an antithrombotic agent in the treatment of thrombosis, treating metastatic cancer, or treating an acute inflammatory reaction. | 2014-10-30 |
20140322220 | Anti-FGFR2 Antibodies and Uses Thereof - The present invention provides antibodies, or antigen-binding antibody fragments thereof, or variants thereof which reduce the cell surface expression of FGFR2 after binding to FGFR2 in both cells overexpressing FGFR2 and cells expressing mutated FGFR2. Also provided are antibody-based therapies for FGFR2-related diseases or conditions such as cancer. Antibodies of the invention also can be used in the diagnostics field. The invention also provides nucleic acid sequences encoding the foregoing antibodies, vectors containing the same, pharmaceutical compositions and kits with instructions for use. | 2014-10-30 |
20140322221 | MULTIVALENT ANTIBODIES AND USES THEREFOR - The present application describes engineered antibodies, with three or more functional antigen binding sites, and uses, such as therapeutic applications, for such engineered antibodies. | 2014-10-30 |